Evidence map›Paper›PMID 42707652›Full record

ReviewTheranostics2026

Micro/nanorobotics for sepsis diagnosis and therapy: a frontier in precision medicine.

Yukun Liu, Kang Wang, Guoyun Wan, Fangli Gao, Huiming Tang, Xiangjun Bai, Zhanfei Li, Yuchang Wang

Abstract readReview
In one paragraph

Review in Theranostics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Yukun LiuDepartment of Plastic and Aesthetic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Kang WangDepartment of Plastic and Aesthetic Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Guoyun WanSchool of Life Science and Technology, Henan Medical University, Xinxiang, 453003, China.
Fangli GaoCollege of Chemistry and Chemical Engineering, Henan Normal University, Xinxiang, 4453007, China.
Huiming TangInstitute of Pharmacology and Clinical Pharmacy, Goethe University Frankfurt, 60438 Frankfurt am Main, Germany.
Xiangjun BaiDivision of Trauma Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Zhanfei LiDivision of Trauma Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
Yuchang WangDivision of Trauma Surgery, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Sepsis is a serious, life-threatening widespread inflammatory response in the body to infection that can result in multiple organ damage and has a relatively high death rate. Traditional antibiotics and supportive treatments have certain deficiencies, such as poor drug accumulation at the site of infection, delayed identification of pathogens, and an inability to precisely regulate the host immune response. New developments in micro- and nanorobotics have provided new paths for sepsis diagnosis and treatment by means of active motion, intelligent sensing and targeted intervention. Biohybrid microrobots containing DNA nanodevices or enzyme sensors can be used for diagnosis to rapidly detect bacterial pathogens, endotoxins and other markers such as procalcitonin. Motivated micro-robots can overcome the biofilm barrier to deliver drugs and increase the local concentration of antibiotics to inhibit bacterial toxins. Functionalised nanobots of cell membrane or enzyme types can target cytokines, reactive oxygen species and circulating mitochondrial DNA to suppress inflammation and organ damage. The above-mentioned multi-functional platforms have combined pathogen clearance, immune modulation and tissue repair into one treatment. Although the above are promising, there are still some problems in biosafety, propulsion efficiency under complex physiological conditions, large-scale production, and the development of clinically relevant animal models. Future work will focus on building intelligent, biocompatible systems capable of autonomous navigation and adaptation to sepsis. Micro- and nanorobots are generally considered to be a new type of devices for treating sepsis that can achieve targeted and personalised therapy through intelligence.

Indexed as

Precision MedicineRoboticsSepsisAnimalsAnti-Bacterial AgentsDrug Delivery SystemsHumansNanomedicineAnti-Bacterial Agentsdrug deliverymicro/nanorobotsnanomedicinesepsistherapy

Identifiers

PMID42707652
PMCPMC13549227

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.